Admedus HPV-vaccine heads to clinical trial

THE ROADHOUSE PHARMACY: Admedus Limited (ASX: AHZ) is to advance its Human Papilloma Virus (HPV) therapeutic vaccine into a Phase Ib study program having made satisfactory progress in preclinical studies.

The HPV Vaccine is designed to target and clear HPV-positive tumour cells.

Admedus said the vaccine has shown exceptional preclinical activity in a series of preclinical models with results demonstrating the therapeutic vaccine prevents disease progression, clears the tumour and inhibits tumour formation.

“The latest preclinical data from the HPV studies is extremely exciting and clearly shows the potential of the technology,” Admedus CEO Lee Rodne said in the company’s announcement to the Australian Securities Exchange.

“We now look forward to taking this program into clinical studies.”

In the TC-1 tumour model, Admedus claims treatment with the HPV vaccine achieved 100 per cent survival and 87.5 per cent (7 of 8) had no detectable tumours after 50 days.

In addition, the vaccine provided 100 per cent protection against HPV-positive tumour cell formation.

Email: info.au@admedus.com

Website: www.admedus.com